Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis UK life sciences: the impact of a cycle of affordability and... The changing landscape for drug pricing and some pointers for the UK life sciences sector.
Views & Analysis The US market in 2027: the evolving pricing and value landsc... An examination of the range of different trends and forces that are acting on the pharmaceutical sector.
Views & Analysis What is ‘affordable’? The reality of the PPRS PPRS impact: has it kept the branded medicines bill within affordable limits?
Views & Analysis Unstable and unpredictable? The reality of the PPRS Has the UK PPRS scheme met its five objectives?
Views & Analysis The rise and fall of PPRS payments How contributions from the updated PPRS have affected the DH budget for the NHS.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
